Functional Recovery Following Intensive Upfront Therapy in Multiple Myeloma Patients With Poor Performance Status: A...

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Newly diagnosed multiple myeloma (MM) patients with severe functional impairment (ECOG performance status [PS] 4) are often excluded from intensive therapy.
• Profound debilitation in MM may be due to reversible disease burden.

Purpose of the Study:

• To evaluate the efficacy and safety of individualized multi-agent regimens in newly diagnosed, bedbound MM patients (ECOG 4).
• To assess the potential for clinical and functional recovery in this patient population.

Main Methods:

• Six newly diagnosed MM patients with ECOG PS 4 received individualized multi-agent regimens including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies.
• Patients had advanced disease features, including skeletal compromise, renal dysfunction, hyperviscosity, and high-risk cytogenetics.

Main Results:

• All patients achieved rapid biochemical responses, with a median M-protein reduction of approximately 75%.
• Five of six patients attained a very good partial response or better, including one complete response.
• Functional recovery paralleled response depth, with median improvement to ECOG PS 2 or better within 10 weeks, regaining ambulation and independence.

Conclusions:

• Severe functional impairment in newly diagnosed MM may reflect reversible disease burden.
• Aggressive, individualized therapy can lead to substantial clinical and functional recovery in patients initially deemed too debilitated for intensive treatment.
• No irreversible treatment-limiting toxicities were observed, supporting the feasibility of intensive therapy in this cohort.